Johnson & Johnson Reports Q4 and Full-Year 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Johnson & Johnson (JNJ) shares gain as Q4 earnings and guidance beats
January 24, 2023 6:52 AM ESTShares of Johnson & Johnson (NYSE: JNJ) rose in pre-open trading Tuesday after the pharmaceutical giant reported better-than-expected fourth-quarter earnings results and earnings guidance.
Fourth quarter sales declined 4.4% to $23.7 billion on unfavorable foreign exchange and reduced COVID-19 vaccine sales. This was below the Wall... More
Johnson & Johnson (JNJ) Tops Q4 EPS by 11c, Revenues Misses; Guides EPS Above Views
January 24, 2023 6:26 AM ESTJohnson & Johnson (NYSE: JNJ) reported Q4 EPS of $2.35, $0.11 better than the analyst estimate of $2.24. Revenue for the quarter came in at $23.7 billion versus the consensus estimate of $23.9 billion.
GUIDANCE:
Johnson & Johnson sees FY2023 EPS of $10.50, versus the consensus of... More
